The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
A review of the efficacy and safety of oral antidiabetic drugs
Open accessAbstract
INTRODUCTION: Additional oral antidiabetic agents to metformin, sulfonylureas (SU) and thiazolidinediones (TZD) are approved for the treatment of type 2 diabetes. AREAS COVERED: The efficacy and safety of metformin, SUs, TZDs, dipeptidyl peptidase-IV (DPP-4) inhibitors, meglitinide analogs, α-glucosidase inhibitors (AGIs), bile-acid sequestrants (BAS) and bromocriptine will be reviewed. EXPERT OPINION: Several new oral agents have been approved for type 2 diabetes management in recent years. It is important to understand the efficacy and safety of these medications in addition to the older agents to best maximize oral drug therapy for diabetes. Of the recently introduced oral hypoglycemic/antihyperglycemic agents, the DPP-4 inhibitors are moderately efficacious compared with mainstay treatment with metformin with a low side-effect profile and have good efficacy in combination with other oral agents and insulin. They are a recommended alternative when metformin use is limited by gastrointestinal (GI) side effects or when SU treatment results in significant hypoglycemia or weight gain. Meglitinide analogs are limited by their frequent dosing, expense and hypoglycemia (repaglinide > nateglinide), while AGIs are also limited by their dosing schedule and GI side-effect profile. BAS and bromocriptine have the lowest efficacy with regard to HbA(1c) reduction, also are plagued by GI adverse reactions, but have a low risk of hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Rosiglitazone was recently withdrawn over concerns of increased risk for myocardial infarction and in 2011 pioglitazone was associated with an increased risk for bladder cancer [9,10].”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Febbraio, M., Podrez, E. A., Smith, J. D., Hajjar, D. P., Hazen, S. L., Hoff, H. F., Sharma, K., & Silverstein, R. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9259 · Cited by 1,044
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
New Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · cited 1×
“Demonstration of the incretin effect occurred in the 1960s when an intrajejunal glucose infusion was found to produce a larger insulin response compared with an equivalent intravenous glucose infusion [13].”
BackgroundFerrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
α-Glucosidase Inhibitors for Patients With Type 2 Diabetes
van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., van de Lisdonk, E. H., Rutten, G. E., & van Weel, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.154 · Cited by 690
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 667
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Holz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567 · cited 1×
“The meglitinide analogs ‘glinides’ are short-acting insulin secretagogues that target one of the main defects that characterizes type 2 diabetes: the progressive loss of early phase prandial insulin secretion [69].”
BackgroundRosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537 · cited 1×
“Further risks associated with TZDs include edema and bone fracture [11,12].”
BackgroundNauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
Hermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., & Sitagliptin Study 035 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00744.x · Cited by 525
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Rosenstock, J., Brazg, R., Andryuk, P. J., Lu, K., & Stein, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.007 · Cited by 514
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes
Lankas, G. R., Leiting, B., Roy, R. S., Eiermann, G. J., Beconi, M. G., Biftu, T., Chan, C.-C., Edmondson, S., Feeney, W. P., He, H., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2988 · Cited by 491
Effect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Medical significance of peroxisome proliferator-activated receptors
Vamecq, J., & Latruffe, N. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10364-1 · Cited by 468
CD26, let it cut or cut it down
De Meester, I., Korom, S., Van Damme, J., & Scharpé, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01486-3 · Cited by 451
Holman, R. R., Cull, C. A., & Turner, R. C. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.960 · Cited by 449
Perfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Chiasson, J.-L., Josse, R. G., Hunt, J. A., Palmason, C., Rodger, N. W., Ross, S. A., Ryan, E. A., Tan, M. H., & Wolever*, T. M. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00004 · Cited by 436
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435 · cited 1×
“A recent meta-analysis was conducted of randomized controlled trials comparing DPP-4 inhibitor therapy with metformin as monotherapy or in combination with other agents [36].”
MethodKennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 427
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416 · cited 1×
“6 Safety and tolerability There are no significant differences in the incidence of overall, serious or drug-related clinical adverse events, including gastrointestinal (GI) events or hypoglycemia in DPP-4- versus placebo-treated patients [28,29,32,41-43].”
BackgroundRosenstock, J., Vico, M., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 408
Strojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406
Drug-Induced Pancreatitis: An Update
Trivedi, C. D., & Pitchumoni, C. S. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000173929.60115.b4 · Cited by 370
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
Fonseca, V., Schweizer, A., Albrecht, D., Baron, M. A., Chang, I., & Dejager, S. (2007) · Diabetologia · doi:10.1007/s00125-007-0633-0 · Cited by 369
Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 363
Tourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60691-6 · Cited by 343
Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van de Lisdonk, E. H., Rutten, G. E., & Van Weel, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003639.pub2 · Cited by 335 · cited 2×
“8%, FPG 20 mg/dl and PPG of 41 mg/dl [110,111].”
BackgroundResultEfficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
Pi-Sunyer, F. X., Schweizer, A., Mills, D., & Dejager, S. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.12.009 · Cited by 312
Henry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 310
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Chen, J., Williams, S., Ho, S., Loraine, H., Hagan, D., Whaley, J. M., & Feder, J. N. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0006-4 · Cited by 307
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · cited 2×
“This increased incidence of hypoglycemia can also be seen when a DPP-4 inhibitor is added to insulin if there is not careful monitoring for adjustment of the insulin dose [45,46].”
BackgroundRoumie, C. L., Hung, A. M., Greevy, R. A., Grijalva, C. G., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00003 · Cited by 300
Del Prato, S., Barnett, A. H., Huisman, H., Neubacher, D., Woerle, H. ‐., & Dugi, K. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01350.x · Cited by 299
Significance of testing platelet functions in vitro
HOLMSEN, H. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb02418.x · Cited by 297
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
Rosenstock, J., Aguilar-Salinas, C., Klein, E., Nepal, S., List, J., Chen, R., & for the CV181-011 Study Investigators (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903178735 · Cited by 288
Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 284
Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors
Scheen, A. J. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01212.x · Cited by 281
Moses, R., Slobodniuk, R., Boyages, S., Colagiuri, S., Kidson, W., Carter, J., Donnelly, T., Moffitt, P., & Hopkins, H. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.119 · Cited by 248
Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., & Jones, M. R. (2008) · Diabetes Care · doi:10.2337/dc08-0283 · Cited by 246
Schweizer, A., Couturier, A., Foley, J. E., & Dejager, S. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02191.x · Cited by 240
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
Chan, J. C. N., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & Williams‐Herman, D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00914.x · Cited by 238
Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl, H., Ohashi, S., Matsuda, M., Miyazaki, Y., Mahankali, A., Kumar, V, Pipek, R., Iozzo, P., Lancaster, J. L., Cincotta, A. H., et al. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1154 · Cited by 238
DeFronzo, R. A., Fleck, P. R., Wilson, C. A., Mekki, Q., & on behalf of the Alogliptin Study 010 Group (2008) · Diabetes Care · doi:10.2337/dc08-1035 · Cited by 227
Johansen, O., Neubacher, D., von Eynatten, M., Patel, S., & Woerle, H.-J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-3 · Cited by 220
Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy
Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E. (2006) · Diabetes Care · doi:10.2337/dc06-1120 · Cited by 219
Frederich, R., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R., Wolf, R., & Mahaffey, K. W. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2138 · Cited by 217
Gaziano, J. M., Cincotta, A. H., O'Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z. J., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 213
Bays, H. E., Goldberg, R. B., Truitt, K. E., & Jones, M. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.18.1975 · Cited by 212
Seck, T., Nauck, M., Sheng, D., Sunga, S., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & for the Sitagliptin Study 024 Group (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02353.x · Cited by 208
Henry, R. R., Lincoff, A. M., Mudaliar, S., Rabbia, M., Chognot, C., & Herz, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60870-9 · Cited by 205
Goldberg, R. B. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.14.1531 · Cited by 197
Garg, A., & Grundy, S. M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-6-199409150-00004 · Cited by 187
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
Niemi, M., Backman, J. T., Granfors, M., Laitila, J., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1181-x · Cited by 186
Repaglinide versus glyburide: a one-year comparison trial
Marbury, T., Huang, W.-C., Strange, P., & Lebovitz, H. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00002-9 · Cited by 185
Repaglinide Versus Nateglinide Monotherapy
Rosenstock, J., Hassman, D. R., Madder, R. D., Brazinsky, S. A., Farrell, J., Khutoryansky, N., Hale, P. M., & for the Repaglinide Versus Nateglinide Comparison Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1265 · Cited by 180
Deeg, M. A., Buse, J. B., Goldberg, R. B., Kendall, D. M., Zagar, A. J., Jacober, S. J., Khan, M. A., Perez, A. T., Tan, M. H., & on behalf of the GLAI Study Investigators (2007) · Diabetes Care · doi:10.2337/dc06-1903 · Cited by 179
Arechavaleta, R., Seck, T., Chen, Y., Krobot, K. J., O’Neill, E. A., Duran, L., Kaufman, K. D., Williams‐Herman, D., & Goldstein, B. J. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01334.x · Cited by 169
Scheen, A. J., Charpentier, G., Östgren, C. J., Hellqvist, Å., & Gause‐Nilsson, I. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1114 · Cited by 168
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1707 · Cited by 166
Aschner, P. J., Katzeff, H. L., Guo, H., Sunga, S., Williams‐Herman, D., Kaufman, K. D., Goldstein, B. J., & for the Sitagliptin Study 049 Group (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01187.x · Cited by 166
Dipeptidylpeptitase-4 Inhibitors (Gliptins): Focus on Drug-Drug Interactions
Scheen, A. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11532980-000000000-00000 · Cited by 166
Efficacy and Safety of Acarbose in Insulin-Treated Patients With Type 2 Diabetes
Kelley, D. E., Bidot, P., Freedman, Z., Haag, B., Podlecki, D., Rendell, M., Schimel, D., Weiss, S., Taylor, T., Krol, A., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2056 · Cited by 164
Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
Graefe‐Mody, U., Retlich, S., & Friedrich, C. (2012) · Clinical Pharmacokinetics · doi:10.2165/11630900-000000000-00000 · Cited by 164
Schweizer, A., Dejager, S., Foley, J. E., Couturier, A., Ligueros‐Saylan, M., & Kothny, W. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01215.x · Cited by 162
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 158
Lee, A., Patrick, P., Wishart, J., Horowitz, M., & Morley, J. E. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00219.x · Cited by 156
White, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.004 · Cited by 152
Desai, N. R., Shrank, W. H., Fischer, M. A., Avorn, J., Liberman, J. N., Schneeweiß, S., Pakes, J., Brennan, T. A., & Choudhry, N. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.07.033 · Cited by 151
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
Engel, S. S., Williams‐Herman, D., Golm, G. T., Clay, R. J., Machotka, S. V., Kaufman, K. D., & Goldstein, B. J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02382.x · Cited by 148
Hoffmann, J., & Spengler, M. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00252-0 · Cited by 148
Covington, P. S., Christopher, R. J., Davenport, M. P., Fleck, P. R., Mekki, Q. A., Wann, E. R., & Karim, A. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.03.004 · Cited by 144
Cincotta, A. H., MEIER, A. H., & Cincotta, M. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1683 · Cited by 144
Hoffmann, J., & Spengler, M. (1994) · Diabetes Care · doi:10.2337/diacare.17.6.561 · Cited by 143
Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
He, Y. (2012) · Clinical Pharmacokinetics · doi:10.2165/11598080-000000000-00000 · Cited by 142
Barzilai, N., Guo, H., Mahoney, E. M., Caporossi, S., Golm, G. T., Langdon, R. B., Williams‐Herman, D., Kaufman, K. D., Amatruda, J. M., Goldstein, B. J., et al. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.568059 · Cited by 139
Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
Meneilly, G. S., Ryan, E. A., Radziuk, J., Lau, D. C. W., Yale, J., Morais, J., Chiasson, J. L., RABASA-LHORET, R. P. R., Maheux, P., Tessier, D., et al. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1162 · Cited by 136
Nowicki, M. P., Rychlík, I., Haller, H. G., Warren, M., Suchower, L. J., Gause‐Nilsson, I. A. M., & Schützer, K.-M. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02812.x · Cited by 134
Deacon, C. F., & Holst, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903463862 · Cited by 131
Gromada, J., Dissing, S., Kofod, H., & Frøkjaer-Jensen, J. (1995) · Diabetologia · doi:10.1007/bf00402171 · Cited by 127
Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000) · PubMed · Cited by 126
Elevated Uric Acid Increases the Risk for Acute Kidney Injury
Lapsia, V., Johnson, R. J., Dass, B., Shimada, M., Kambhampati, G., Ejaz, N. I., Arif, A. A., & Ejaz, A. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.06.021 · Cited by 119
Hasslacher, C., & for the Multinational Repaglinide Renal Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.3.886 · Cited by 117
Enc, F. Y., I˙meryüz, N., Akın, H. L., Turoğlu, H. T., Dede, F., Haklar, G., Tekkeşin, N., ̇roğlu, N. B., Yeğen, B. Ç., Rehfeld, J. F., et al. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.281.3.g752 · Cited by 116
Rifampin decreases the plasma concentrations and effects of repaglinide
Niemi, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111183 · Cited by 115
Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
Marfella, R., Barbieri, M., Grella, R., Rizzo, M. R., Nicoletti, G. F., & Paolisso, G. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2009.01.004 · Cited by 113
Shang, Q., Saumoy, M., Holst, J. J., Salen, G., & Xu, G. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00362.2009 · Cited by 111
Acarbose in the treatment of elderly patients with type 2 diabetes
Josse, R. G., Chiasson, J.-L., Ryan, E. A., Lau, D. C. W., Ross, S. A., Yale, J.-F., Leiter, L. A., Maheux, P., Tessier, D., Wolever, T. M. S., et al. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00176-6 · Cited by 110
Hatorp, V., Hansen, K. T., & Thomsen, M. S. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003253704 · Cited by 110
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.006 · Cited by 106
Cincotta, A. H., Schiller, B. C., & MEIER, A. H. (1991) · Metabolism · doi:10.1016/0026-0495(91)90057-4 · Cited by 106
Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
Boulton, D. W., Li, L., Frevert, E. U., Tang, A., Castaneda, L., Vachharajani, N. N., Kornhauser, D. M., & Patel, C. G. (2011) · Clinical Pharmacokinetics · doi:10.2165/11584350-000000000-00000 · Cited by 105
Luo, S., MEIER, A. H., & Cincotta, A. H. (1998) · Neuroendocrinology · doi:10.1159/000054344 · Cited by 102
Niemi, M., Kajosaari, L. I., Neuvonen, M., Backman, J. T., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02027.x · Cited by 97
Efficacy and Safety of Acarbose in Metformin-Treated Patients With Type 2 Diabetes
Rosenstock, J., Brown, A., Fischer, J., Jain, A., Littlejohn, T., Nadeau, D., Sussman, A., Taylor, T., Krol, A., & Magner, J. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2050 · Cited by 93
Scheen, A. J. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746020-00001 · Cited by 93
Drug Interactions with Colesevelam Hydrochloride, a Novel, Potent Lipid-Lowering Agent
Donovan, J. M., Stypinski, D., Stiles, M. R., Olson, T. A., & Burke, S. K. (2000) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007831418308 · Cited by 93
Banerjee, S., Wang, D. W., Alzamora, R., Huang, X. N., Pastor‐Soler, N. M., Hallows, K. R., McGaffin, K. R., & Ahmad, F. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.06.003 · Cited by 93
Coniff, R. F., Shapiro, J. A., & Seaton, T. B. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420210080009 · Cited by 90
Halimi, S., Berre, M.-A. L., & Grange, V. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00163-7 · Cited by 85
Repaglinide in Type 2 Diabetes: A 24-Week, Fixed-Dose Efficacy and Safety Study
Jovanovic, L. G., Dailey, G., Huang, W. C., Strange, P., & Goldstein, B. J. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008694 · Cited by 84
Phillips, P., Karrasch, J., Scott, R., Wilson, D., & Moses, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.2.269 · Cited by 82 · cited 1×
“9% from placebo, with an average reduction in FPG and PPG from placebo of about 30 mg/dl [104-107].”
BackgroundDhillon, S., & Weber, J. (2009) · Drugs · doi:10.2165/11201170-000000000-00000 · Cited by 82
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study
Madsbad, S., Kilhovd, B. K., Lager, I., Mustajoki, P., Dejgaard, A., & for the Scandinavian Repaglinide Group (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00490.x · Cited by 80
Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39254-7 · Cited by 78 · cited 11×
“This review will predominantly focus on the efficacy and safety of DPP-4 inhibitors, 10.1517/14740338.2013.752813 © 2013 Informa UK, Ltd. ISSN 1474-0338, e-ISSN 1744-764X 153 All rights reserved: reproduction in whole or in part not permitted meglitinide analogs, AGIs, BAS and bromocriptine but will also address metfo…”
BackgroundInfluentialTreatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone
Jovanovic, L. G., Hassman, D. R., Gooch, B. R., Jain, R., Greco, S. N., Khutoryansky, N., & Hale, P. M. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.09.004 · Cited by 78
Moses, R. G., Gomis, R., Frandsen, K. B., Schlienger, J.-L., & Dedov, I. I. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.11 · Cited by 71
Treatment of Patients Over 64 Years of Age With Type 2 Diabetes
Prato, S. D., Heine, R. J., Keilson, L., Guitard, C., Shen, S. G., & Emmons, R. P. (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2075 · Cited by 67
Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
de Laar, F. A. V., Lucassen, P. L., Akkermans, R., van de Lisdonk, E. H., Rutten, G. E. H. M., & van Weel, C. (2005) · Cochrane Database of Systematic Reviews · Cited by 65
Owens, D. R., Luzio, S. D., Ismail, I. S., & Bayer, A. J. (2000) · Diabetes Care · doi:10.2337/diacare.23.4.518 · Cited by 64
Glucagon-like peptide-1 (7–36 amide): a potent glucagonostatic and insulinotropic hormone
Matsuyama, T., Komatsu, R., Namba, M., Watanabe, N., Itoh, H., & Tarui, S. (1988) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(88)80063-9 · Cited by 64
Derosa, G., Mugellini, A., Ciccarelli, L., Crescenzi, G., & Fogari, R. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(03)00057-3 · Cited by 62
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Migoya, E. M., Stevens, C., Bergman, A. J., Luo, W., Lasseter, K. C., Dilzer, S. C., Davies, M. J., Wagner, J. A., & Herman, G. A. (2009) · PubMed · Cited by 58
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load
Derosa, G., Maffioli, P., Ferrari, I., Fogari, E., D’Angelo, A., Palumbo, I., Randazzo, S., Bianchi, L., & Cicero, A. F. G. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.11.015 · Cited by 57
Staels, B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.suppl53.290 · Cited by 52
Does Bromocriptine Improve Glycemic Control of Obese Type-2 Diabetics?
Aminorroaya, A., Janghorbani, M., Ramezani, M., Haghighi, S., & Amini, M. (2004) · Hormone Research in Paediatrics · doi:10.1159/000078932 · Cited by 50
Patel, C., Li, L., Girgis, S., Kornhauser, D. M., Frevert, E. U., & Boulton, D. W. (2011) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s15227 · Cited by 45
Wilding, J. P. H., Gause‐Nilsson, I. A. M., & Persson, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.040 · Cited by 45
Long, G. G., Reynolds, V. L., López‐Martinez, A., Ryan, T. E., White, S. L., & Eldridge, S. R. (2008) · Toxicologic Pathology · doi:10.1177/0192623307311757 · Cited by 44
Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes
Goldfine, A. B., Fonseca, V. A., Jones, M. R., Wang, A. C., Ford, D. M., & Truitt, K. E. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1241195 · Cited by 40
Impairment of Absorption of Digoxin by Acarbose
Miura, T., Ueno, K., Tanaka, K., Sugiura, Y., Mizutani, M., Takatsu, F., Takano, Y., & Shibakawa, M. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04474.x · Cited by 39
Rigby, S. P., Handelsman, Y., Lai, Y., Abby, S. L., Tao, B., & Jones, M. R. (2009) · Endocrine Practice · doi:10.4158/ep09146.or · Cited by 39
Schwarz, S. L., Gerich, J. E., Marcellari, A., Jean-Louis, L., Purkayastha, D. S., & Baron, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00792.x · Cited by 39
Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine
Weitzman, S. P., Ginsburg, K. C., & Carlson, H. E. (2009) · Thyroid · doi:10.1089/thy.2008.0312 · Cited by 35
Pharmacokinetics of Nateglinide in Renally Impaired Diabetic Patients
Devineni, D., Walter, Y. H., Smith, H. T., Lee, J. S., Prasad, P., & McLeod, J. F. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270002239825 · Cited by 35
Ducray, P. S., D’ardhuy, X. L., Jamois, C., & Banken, L. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.259 · Cited by 31
Costa, B., & Piñol, C. (1997) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(97)00083-1 · Cited by 30
Acute Hepatotoxicity Caused by Repaglinide
Nan, D., Hernández, J. L., Fernández‐Ayala, M., & Carrascosa, M. F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00024 · Cited by 26
Brown, K. S., Armstrong, I., Wang, A., Walker, J. R., Noveck, R. J., Swearingen, D., Allison, M. J., Kissling, J., Kisicki, J. C., & Salazar, D. E. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009349378 · Cited by 24
Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
Ramteke, K., Ramanand, S. J., Ramanand, J. B., Jain, S., Raparti, G., Patwardhan, M., Murthy, M., & Ghanghas, R. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83062 · Cited by 22
Rubin, C. J., Ledeine, J.-M., & Fiedorek, F. T. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.028 · Cited by 17
Cholestatic Hepatitis Associated With Repaglinide
López-García, F., Borrás, J., Verdú, C., Salazar, V. R., Ruiz, J. A., Sales, J., Lucena, M. I., & Andrade, R. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.752-a · Cited by 15
Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients
Takei, I., Miyamoto, K., Funae, O., Ohashi, N., Meguro, S., Tokui, M., & Saruta, T. (2001) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00148-9 · Cited by 14
Repaglinide induced Acute Hepatotoxicity
Jaiswal, S., Mehta, R. S., Musuku, M. R., Tran, L., & McNamee, J. W. (2009) · Journal of Nepal Medical Association · doi:10.31729/jnma.236 · Cited by 8
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
Journal, C. (2008) · Core evidence · doi:10.2147/ce.s7443 · Cited by 6
An Unusual Initial Manifestation of Acute Leukemia
Desai, A., Desai, A., Staszewski, H., & Cunha, B. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.025 · Cited by 4
Cited by
Adisakwattana, S. (2017) · Nutrients · doi:10.3390/nu9020163 · Cited by 311
Pharmacological treatment of diabetes in older people
Valencia, W. M., & Florez, H. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12362 · Cited by 62
Wang, Y., Karmakar, T., Ghosh, N., Basak, S., & Gopal Sahoo, N. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2021.131376 · Cited by 35
Amelioration of Endothelial Dysfunction in Diabetes: Role of Takeda G Protein–Coupled Receptor 5
Cai, Z., Yuan, S., Zhong, Y., Deng, L., Li, J., Tan, X., & Feng, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.637051 · Cited by 23
Kiyosue, A., Seino, Y., Nishijima, K., Bosch‐Traberg, H., & Kaku, K. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12759 · Cited by 5
Metadata
- Authors
- Stein, S. A., Lamos, E. M., & Davis, S. N.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2012-12-14
- Volume
- 12
- Issue
- 2
- Pages
- 153-175
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2167706579
- Cited by
- 305
- References
- 155
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.